People · Operator
Named in public records as an officer, director or promoter · active 2010–2019 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sight Sciences, Inc. | — | Biotechnology | Series B | $111.3M | $777.8M | 2019 |
| Dnanexus, Inc. | — | Biotechnology | Series A | $31.6M | $542.3M | 2015 |
| Baxano, Inc. | — | Other Health Care | Series B | $28.5M | $631.4M | 2010 |
| BioEclipse Therapeutics, Inc. | — | Biotechnology | Series A | $10.1M | $366.1M | 2019 |
Stephen Thau at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Thau on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carter Meyer | 1 | 14 |
| Michael Goldberg | 1 | 11 |
| Russell Hirsch | 1 | 10 |
| ROB HAYES | 1 | 9 |
| David Clapper | 1 | 6 |
| Andrew ` Offer | 1 | 5 |
| JAMES SHAPIRO | 1 | 5 |
| Geoff Duyk | 1 | 5 |
| Krishna Yeshwant | 1 | 5 |
| Elona Baum | 1 | 5 |
| Biao He | 1 | 5 |
| William Harrington | 1 | 4 |
| Paul Badawi | 1 | 4 |
| Mark Frohlich | 1 | 3 |
| Catherine Sohn | 1 | 3 |
| Richard Daly | 1 | 3 |
| Vahid Saadat | 1 | 2 |
| Erica Rogers | 1 | 2 |
| Jesse Selnick | 1 | 2 |
| Frank Phillips | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.